智通财经APP讯，君实生物(01877)发布公告，近日，公司已完成发行2026年度第一期科技创新债券，募 集资金已于2026年1月26日到账。2026年度第一期科技创新债券发行总金额为人民币10亿元，期限为 3+2年，于2031年1月26日到期，发行利率为2.70%。 ...

君实生物(01877)发布公告，近日，公司已完成发行2026年度第一期科技创新债券，募集资金已于2026 年1月26日到账。2026年度第一期科技创新债券发行总金额为人民币10亿元，期限为3+2年，于2031年1 月26日到期，发行利率为2.70%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 茲提述本公司日期為2025年12月28日就獲中國銀行間市場交易商協會接受註冊中 期票據的公告（「該公告」）。除另有界定外，本公告所用詞彙與該公告所用者具有 相同涵義。 本公司董事會欣然宣布，近日，本公司已完成發行2026年度第一期科技創新債 券，募集資金已於2026年1月26日到賬。2026年度第一期科技創新債券發行總金 額為人民幣10億元，期限為3+2年，於2031年1月26日到期，發行利率為2.70%。 本公司股東及有意投資者於買賣本公司證券時務請審慎行事。 承董事會命 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 2026年度第一期科技創新債券完成發行 本公告由上海君實生物醫藥科技股份有限公司（「本公司」）自願作出。請亦參見本 公司於2026年1月26日刊發的海外監 ...

Core Viewpoint - Bristol-Myers Squibb (BMS) has initiated two new Phase III clinical trials (ROSETTA Lung-201 and ROSETTA Lung-202) for Pumitamig, a PD-L1/VEGF-A dual antibody, indicating a strong commitment to advancing its oncology pipeline [1][7]. Group 1: Clinical Trials - ROSETTA Lung-201 aims to enroll 850 patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after platinum-based chemotherapy, evaluating the efficacy and safety of Pumitamig compared to durvalumab as a subsequent treatment [1][8]. - ROSETTA Lung-202 plans to include 750 previously untreated patients with advanced NSCLC and PD-L1 expression ≥50%, assessing the efficacy and safety of Pumitamig versus pembrolizumab as a first-line treatment [3][10]. Group 2: Development History - Pumitamig was initially discovered by Prometheus Biosciences, which granted global development, production, and commercialization rights outside of China to BioNTech in November 2023. Prometheus was subsequently acquired by BioNTech for a total of $950 million [1][8]. - In June 2025, BMS acquired global collaboration and commercialization rights for Pumitamig from BioNTech for $11.1 billion, highlighting the strategic value placed on this asset [1][8]. Group 3: Competitive Landscape - To date, Pumitamig has been involved in five head-to-head Phase II/III or III clinical trials against PD-(L)1 drugs, with positive control drugs including pembrolizumab, nivolumab, durvalumab, and atezolizumab [5][12]. - BMS is noted for its proactive approach in advancing clinical development for introduced products, particularly in the context of PD-(L)1 dual antibodies [5][12].

| 债券全称 | 上海君实生物医药科技 股份有限公司 年度 2026 第一期科技创新债券 | | | 债券简称 | 君实生物 26 | (科创债) | MTN001 | | --- | --- | --- | --- | --- | --- | --- | --- | | 代码 | 102680280 | | | 期限 | | 年 3+2 | | | 起息日 | 2026 年 1 日 | 月 | 26 | 兑付日 | 2031 | 年 1 月 | 26 日 | | 计划发行总额 （万元） | 100,000.00 | | | 实际发行总额 （万元） | | 100,000.00 | | 1 证券代码：688180 证券简称：君实生物 公告编号：临 2026-002 上海君实生物医药科技股份有限公司 关于 2026 年度第一期科技创新债券发行结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）2024 年年度股东 大会审议通过了《关于发行境内外债务融资工具的一般性授 ...

Core Viewpoint - The vaccine sector is experiencing strong performance due to the emergence of Nipah virus cases in India, leading to increased investment in related biopharmaceutical ETFs [1][3]. Group 1: Market Performance - The biopharmaceutical ETF Huatai (159839) saw a significant increase of 2.13% with a trading volume exceeding 60 million yuan, marking a 133% increase compared to the previous period [1]. - The ETF received a net subscription of 16.5 million shares today, accumulating nearly 40 million yuan in the last five days [1]. - Major component stocks of the ETF showed positive performance, with Zhifei Biological rising nearly 15%, Watson Bio increasing over 11%, and Hualan Biological up nearly 7% [3]. Group 2: Nipah Virus Impact - Five confirmed cases of Nipah virus infection have been reported in West Bengal, India, including healthcare workers, with nearly 100 individuals under home quarantine [3]. - The Nipah virus can attack the lungs and brain, with symptoms including fever, headache, drowsiness, and confusion, and a mortality rate of over 40% [3]. - There is currently no specific vaccine or effective treatment for the Nipah virus [3]. Group 3: Vaccine Development and Innovation - Hualan Biological received approval for clinical trials of its recombinant shingles vaccine, while Zhifei Biological's CA111 injection has entered Phase I clinical trials [7]. - The vaccine industry is focusing on technological upgrades and exploring new markets, particularly in the Middle East [8]. - The growth of the vaccine sector is expected to be driven by the increasing immunization needs of the aging population, shifting focus from children to a broader demographic [8]. Group 4: mRNA Vaccine Developments - Recent positive clinical data from mRNA vaccine leaders indicate a breakthrough development window for therapeutic cancer vaccines [9]. - mRNA technology offers significant advantages over traditional methods, including rapid production capabilities and enhanced safety profiles [9].

Group 1 - The biovaccine sector saw an increase of 2.98%, ranking 9th among concept sectors, with 45 stocks rising, including Hualan Vaccine and Jindike, which hit the 20% limit up [1] - Leading stocks in the biovaccine sector included Zhifei Biological, Dongfang Biological, and CanSino, which rose by 14.87%, 12.36%, and 11.67% respectively [1] - The sector experienced a net inflow of 1.305 billion yuan from main funds, with 36 stocks receiving net inflows, and five stocks exceeding 100 million yuan in net inflow [2] Group 2 - The top net inflow stock was Watson Bio, with a net inflow of 297 million yuan, followed by Zhifei Biological, Junshi Biological, and Hualan Vaccine with net inflows of 261 million yuan, 169 million yuan, and 143 million yuan respectively [2] - The net inflow ratios for Hualan Vaccine, Junshi Biological, and Keqian Biological were 23.86%, 15.20%, and 14.32% respectively, indicating strong investor interest [3] - The biovaccine sector's performance was contrasted by declines in other sectors, such as military information technology and commercial aerospace, which fell by 4.70% and 3.56% respectively [2]

公开资料显示，尼帕是人畜共患的RNA病毒，主要由果蝠和猪携带，死亡率在40%至75%之间，潜伏期 一般为4天至14天。目前尚无专门的疫苗和有效疗法，治疗侧重于控制症状和提供支持性护理。 部分医药股午后拉升。截至发稿，康希诺生物(06185)涨10.13%，报40.86港元；君实生物(01877)涨 5.19%，报23.92港元；复旦张江(01349)涨4.11%，报3.29港元。 消息面上，1月26日，印度出现尼帕病毒疫情相关话题冲上热搜，引发关注。据新华社报道，印度出现 尼帕病毒疫情。邻近国家正严阵以待。感染者集中在印度西孟加拉邦。截至本文发稿，确诊感染病例已 达5例，至少一人病情危重，另有近百人被要求居家隔离。 ...

每经AI快讯，港股部分医药股午后拉升。截至发稿，康希诺生物(06185.HK)涨10.13%，报40.86港元； 君实生物(01877.HK)涨5.19%，报23.92港元；复旦张江(01349.HK)涨4.11%，报3.29港元。 ...

消息面上，1月26日，印度出现尼帕病毒疫情相关话题冲上热搜，引发关注。据新华社报道，印度出现 尼帕病毒疫情。邻近国家正严阵以待。感染者集中在印度西孟加拉邦。截至本文发稿，确诊感染病例已 达5例，至少一人病情危重，另有近百人被要求居家隔离。 公开资料显示，尼帕是人畜共患的RNA病毒，主要由果蝠和猪携带，死亡率在40%至75%之间，潜伏期 一般为4天至14天。目前尚无专门的疫苗和有效疗法，治疗侧重于控制症状和提供支持性护理。 智通财经APP获悉，部分医药股午后拉升。截至发稿，康希诺生物(06185)涨10.13%，报40.86港元；君 实生物(01877)涨5.19%，报23.92港元；复旦张江(01349)涨4.11%，报3.29港元。 ...